Curis | CRIS - Cash And Equivalent


Curis reported $10.14M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 1.38M 553K Dec/2025
Amgen USD 12.04B 2.91B Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bayer EUR 5.9B 1.34B Sep/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
CSL USD 2.16B 633M Jun/2025
Curis USD 10.14M 10.14M Jun/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Exelixis USD 482.49M 106.19M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
TG Therapeutics USD 442.21M 242.7M Mar/2026
Verastem USD 204.99M 67.28M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024